Atlas Trials

Safety of Tofacitinib, an Oral Janus Kinase Inhibitor, in Primary Sjogren's Syndrome

Clinical trial NCT04496960 · ACTIVE_NOT_RECRUITING

Trial details

NCT number
NCT04496960
Sponsor
National Institute of Dental and Craniofacial Research (NIDCR)
Status
ACTIVE_NOT_RECRUITING
Phase
Phase 1, Phase 2
Study type
INTERVENTIONAL
Sjogren's Syndrome
Start date
2021-05-18
Primary completion
2025-01-14
Enrollment
23

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.